Amgen Inc
NASDAQ:AMGN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
262.75
337.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Amgen Inc
Amgen Inc
Accrued Liabilities
Amgen Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Accrued Liabilities
$988.3m
|
CAGR 3-Years
32%
|
CAGR 5-Years
37%
|
CAGR 10-Years
47%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3.2B
|
CAGR 3-Years
27%
|
CAGR 5-Years
22%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
25%
|
CAGR 10-Years
24%
|
|
Amgen Inc
Glance View
Amgen Inc., a leader in the biopharmaceutical industry, has spent over four decades revolutionizing the way we approach complex diseases. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen harnesses the power of human biology to develop innovative therapies for serious illnesses. Its robust portfolio features groundbreaking products that target diseases such as cancer, kidney disease, and rheumatoid arthritis. Notably, Amgen's flagship drugs, like Enbrel and Neulasta, have garnered significant market presence, contributing to the company’s solid financial performance. The firm’s commitment to research and development is underscored by its considerable investments in biotechnology, yielding a promising pipeline of future treatments that aim to improve patient lives while also providing strong returns for investors. As a powerhouse in the healthcare sector, Amgen stands out not just for its scientific advancements, but also for its strategic approach to growth. The company has embraced a culture of continuous improvement and collaboration, forming partnerships that enhance its market reach and innovation potential. With a focus on sustainable practices, Amgen is dedicated to ensuring that its operations are environmentally responsible while also delivering durable financial results. Its steady revenue growth and focus on shareholder return further bolster its profile as an attractive investment option. As healthcare demands evolve and an increasing global population seeks better treatments, Amgen is well-positioned to capitalize on these opportunities, making it a compelling choice for investors looking to navigate the dynamic biotech landscape.
See Also
What is Amgen Inc's Accrued Liabilities?
Accrued Liabilities
14.6B
USD
Based on the financial report for Sep 30, 2024, Amgen Inc's Accrued Liabilities amounts to 14.6B USD.
What is Amgen Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
11%
Over the last year, the Accrued Liabilities growth was 3%. The average annual Accrued Liabilities growth rates for Amgen Inc have been 16% over the past three years , 14% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
